Form 4: Allogene Therapeutics SVP, General Counsel Douglas Earl Martin Reports Sale of Shares to Cover Tax Obligations

Douglas Earl Martin, SVP, General Counsel of Allogene Therapeutics, Inc., reports selling 6,404 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On February 3, 2025, Douglas Earl Martin, SVP, General Counsel of Allogene Therapeutics, Inc., sold 6,404 shares of common stock.
• The sale was executed at a price of $1.71 per share.
• The transaction was conducted to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following the transaction, Martin directly owns 587,848 shares of Allogene Therapeutics, Inc.
• The sale was mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary trade by the reporting person.

Sentiment

Score: 5

Explanation: Neutral sentiment as the filing relates to a routine transaction for tax obligations.

Management Comments

• The sale is mandated by the Issuer's election under its equity incentive plant to require the satisfaction of tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary trade by the reporting person.

Industry Context

This is a routine transaction related to executive compensation and tax obligations, common in publicly traded companies.

Stakeholder Impact

• The sale of shares by an executive could have a minor impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale.

Key Dates